Platinum Priority – Prostate CancerEditorial by Alan Dal Pra, Matthew Abramowitz and Alan Pollack on pp. 419–422 of this issueEffect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial
Introduction
In western countries, prostate cancer (PCa) is the most common form of cancer among men of 50 yr and older, with a mortality-to-incidence ratio of 20% [1]. Worldwide, an estimated 1.1 million cases were diagnosed in 2012 [2]. Although the widespread use of prostate-specific antigen (PSA) testing has led to earlier detection of PCa, in 2015 still 16% of patients with PCa in The Netherlands presented with bone metastatic disease at first diagnosis. The current standard treatment for metastatic disease is systemic therapy with androgen deprivation therapy (ADT) that, at present, is frequently combined with docetaxel or abiraterone [3], [4], [5].
Treatment of the primary prostatic tumour is not standard practice in those with metastatic disease, although local therapy has been proven to prolong overall survival in other primary metastasised malignancies [6], [7], [8], [9]. During the Advanced Prostate Cancer Consensus Conference 2017, however, 69% of panellists suggested that radical local treatment should be regarded as the appropriate type of treatment for patients with newly diagnosed oligometastatic prostate cancer [10]. In addition, 48% of panellists considered radical local treatment in men with de novo asymptomatic high-volume metastatic prostate cancer. To date, no randomised controlled trials (RCTs) have been published to address the potential benefits of simultaneous local treatment of the prostate complementary to ADT.
The current RCT was based on the hypothesis that in patients with primary bone metastatic PCa (mPCa), the oncological outcome might be improved by administrating radical radiotherapy (RT) to the primary tumour in addition to standard ADT. The HORRAD trial is a multicentre prospective RCT that studies the efficacy of external beam radiation therapy (EBRT) to the prostate in addition to standard ADT in patients with mPCa, with overall survival as the primary outcome.
Section snippets
Trial design and participants
The HORRAD trial is a multicentre prospective RCT. Patients were recruited in 28 centres across The Netherlands. Patients were eligible if they had a previously untreated, histologically confirmed diagnosis of adenocarcinoma of the prostate with any number of bone metastases on bone scintigraphy. Tumours could be of any grade (Gleason score 6–10) and T stage (cT1-cT4; cN0-cN1; M1) [11].
Exclusion criteria were age >80 yr; PSA <20 ng/ml; previous treatment for prostate cancer; insufficient
Patients characteristics
Between November 2004 and September 2014, 446 patients diagnosed with mPCa were assessed for eligibility in 28 participating centres. Six patients were excluded because of either a second malignancy (n = 2), absence of osseous metastases (n = 2), or unknown screening failure (n = 2). Eight patients declined to participate, despite having previously given informed consent. The remaining 432 patients were randomly assigned to either ADT with EBRT (RT group, n = 216) or ADT alone (control group, n = 216).
Discussion
This is the first RCT in patients with mPCa evaluating local treatment of the primary tumour along with ADT compared to ADT alone, with overall survival as the primary endpoint. No overall survival benefit was shown for concurrent local treatment after a median follow-up time of 47 mo. Median overall survival was 45 mo (95% CI: 40.4–49.6) in the RT group and 43 mo (95% CI: 32.6–53.4) in the control group (p = 0.4).
The results of our RCT differ from those in the recent literature, where various
Conclusions
The current randomised trial comparing ADT to ADT with EBRT to the prostate in patients with primary mPCa showed no significant difference in overall survival, although the CI cannot exclude a substantial survival benefit. Further research is needed to confirm our findings.
Author contributions: Liselotte M.S. Boevé had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Hulshof,
References (29)
- et al.
Global burden of urologic cancers, 1990–2013
Eur Urol
(2017) - et al.
EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer
Eur Urol
(2017) - et al.
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Lancet Oncol
(2015) - et al.
Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial
Lancet
(2001) - et al.
Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
Eur Urol
(2018) - et al.
CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials
Int J Surg
(2011) - et al.
An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer
Eur J Cancer
(2008) - et al.
Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study
Eur Urol
(2014) - et al.
Radical prostatectomy or external beam radiation therapy versus no local therapy for survival benefit in metastatic prostate cancer: a SEER-Medicare analysis
J Urol
(2015) - et al.
The impact of local treatment on overall survival in patients with metastatic prostate cancer on diagnosis: a national cancer data base analysis
Eur Urol
(2017)
Role of radical prostatectomy in metastatic prostate cancer: data from the Munich cancer registry
Eur Urol
Local therapy improves survival in metastatic prostate cancer
Eur Urol
Escalated-dose conformal radiotherapy for localised prostate cancer: long-term overall survival results from the MRC RT01 randomised controlled trial
Eur J Cancer
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012
Int J Cancer
Cited by (353)
Indication and perspectives of radiation therapy in the setting of de-novo metastatic prostate cancer
2024, Cancer/RadiotherapieThe role of radiation therapy for de novo metastatic bladder and renal cancers
2024, Cancer/RadiotherapieManagement of metastatic prostate cancer: State-of-the-art
2024, Bulletin de l'Academie Nationale de MedecineEstablishing a Role for Radical Prostatectomy in Low-volume Metastatic Disease: From Premise to Proof?
2024, European Urology Open Science